Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopha
To evaluate the long-term local control, survival rate, acute and late radiation related toxicities, quality of life after reducing high risk primary tumor clinical target volumes (CTVp1) in non-metastatic nasopharyngeal carcinoma treated with IMRT.
| Condition(s) | Nasopharyngeal Carcinoma, Intensity-Modulated Radiotherapy |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | To evaluate the long-term local control, survival rate, acute and late radiation related toxicities, quality of life after reducing high risk primary tumor clinical target volumes (CTVp1) in non-metastatic nasopharyngeal carcinoma treated with IMRT. |
| Who can participate | Inclusion Criteria: 1. histologic confirmation of nonkeratinizing nasopharyngeal carcinoma(WHO II-III); 2. newly diagnosed stage I to IVa according to the American Joint Committee on Cancer-Union for International Cancer Control 8th edition stage-classification system 3. nasopharyngeal mass confined to one side of nasopharynx and did not exceed the midline(the line between the nasal septum and the midpoint of spinal cord/medulla) detected by electronic nasopharyngoscope (ENS) and magnetic resonance imaging (MRI). Pathological biopsy was recommended if it was unclear whether tumor invaded the contralateral side radiographically. 4. planned to receive curative IMRT, Chemotherapy drugs should be administered according to Chinese Society of Clinical Oncology (CSCO) guidelines depending on the |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Lead sponsor | Zhongshan People's Hospital, Guangdong, China |
| Locations | Zhongshan, Guangdong, China |
| Start date | 2023-08-04 |
| NCT ID | NCT05994170 |
| Official listing | https://clinicaltrials.gov/study/NCT05994170 |